If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Olumiant ® (baricitinib) tablets
1mg, 2mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
OLUMIANT® (baricitinib): Formulation
Olumiant (baricitinib) is supplied as debossed, film-coated, immediate-release tablets available in 2 mg (Olumiant Package Insert, 2018).
Olumiant Prescribing Information
See important safety information, including boxed warning, in the attached prescribing information.
Description of Baricitinib Tablet
Each tablet has a recessed area on both sides of the tablet surface.1
Baricitinib 2-mg tablets are
light pink in color
oblong in shape, and
not scored.1
Baricitinib 2-mg tablets have a “Lilly” designation on one side and a “2” designation on the other side of the tablet surface.1
Baricitinib 1-mg tablets are
very light pink in color
round in shape, and
not scored.1
Baricitinib 1-mg tablets have a “Lilly” designation on one side and a “1” designation on the other side of the tablet surface.1
Description of Baricitinib Packaging
Baricitinib 2-mg tablets are supplied in bottles of 30 (NDC: 0002-4182-30).1
Baricitinib 1-mg tablets are supplied in bottles of 30 (NDC: 0002-4732-30).1
Enclosed Prescribing Information
OLUMIANT® (baricitinib) tablets, for oral use, Lilly
1. Olumiant [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
Glossary
NDC = National Drug Code
Date of Last Review: October 07, 2019
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 8am - 7pm ET
